Immunic drug targeting post-COVID syndrome in Phase 2 trial - ICYMI

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler joined Proactive to discuss a research update for the company's lead compound vidofludimus calcium. Vidofludimus calcium is being supplied for an investigator-sponsored Phase 2 clinical trial focused on treating post-COVID syndrome (PCCS). The drug is also currently in Phase 3 trial for Multiple Sclerosis (MS). Proactive: You have announced the start of an investigator-sponsored Phase 2 clinical trial for vidofludimus calcium. Can you tell u ...